Supernus Pharmaceuticals Net Change in Long-Term Investments 2011-2024 | SUPN
Supernus Pharmaceuticals net change in long-term investments from 2011 to 2024. Net change in long-term investments can be defined as the net cash flows from the sale and purchase of investments with maturities greater than one year.
Supernus Pharmaceuticals Annual Net Change in Long-Term Investments
(Millions of US $) |
| 2024 |
$N/A |
| 2023 |
$N/A |
| 2022 |
$N/A |
| 2021 |
$13 |
| 2020 |
$-15 |
| 2019 |
$N/A |
| 2018 |
$N/A |
| 2017 |
$N/A |
| 2016 |
$N/A |
| 2015 |
$N/A |
| 2014 |
$N/A |
| 2013 |
$N/A |
| 2012 |
$N/A |
| 2011 |
$N/A |
| 2010 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.805B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
